Global burden of Alzheimer’s disease and other dementias attributed to metabolic risks from 1990 to 2021: results from the global burden of disease study 2021 Authors: Xinyi Zhang, Tongtong Guo, Ya Zhang, Min Jiao, Lihong Ji, Zhiwei Dong, Haiyan Li, Shanquan Chen, Wengui Zheng, Qi Jing Published: 2024 ABSTRACT ObjectiveThe risk of Alzheimer’s disease (AD) and other dementias increases with greater global exposure to metabolic risks, making this a crucial public health issue. This study aimed to report the metabolism-attributable global burden of AD and other dementias from 1990 to 2021.MethodsThe Global Burden of Disease Study (GBD) 2021 collected data on the number of deaths and disability-adjusted life-years (DALYs) related to AD and other dementias caused by metabolic risks, including high fasting plasma glucose (FPG) and high body mass index (BMI). The analysis assessed the disease burden and temporal patterns worldwide, examining data by region, country, level of social development, age group, and sex.ResultsGlobally, the count of AD and other dementia-related deaths due to metabolic risks grew from 98,608 to 399,824, a 4.1-fold increase. For dementias related to high FPG and high BMI, the age-standardized mortality rates (ASMR) and age-standardized DALY rate (ASDR) increased with age and were higher in females than in males. In 2021, the highest burden was observed in high-income North America. The ASMR and ASDR have grown worldwide between 1990 and 2021. The burden of metabolism-related AD and other dementias was positively correlated with the Socio-Demographic Index (SDI), with higher ASMR and ASDR in high SDI regions but showing more pronounced increases in low and low-middle SDI regions.ConclusionsMetabolism-related global burden of AD and other dementias is increasing, particularly among women and in high-income regions. Targeted prevention programs for dementia should be developed, along with early interventions for risk factors.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12888-024-06375-x. Introduction Alzheimer’s disease (AD) and other dementias are the seventh leading cause of death globally, having affected more than 55 million people. The cost of dementia will rise to exceed $2.8 trillion by 2030 [1]. The poor health and high expense of care caused by dementia place significant pressure on families, communities, healthcare systems, and social safety nets [2]. Despite substantial progress in the identification and treatment of this disorder, dementia remains incurable. “Prevention is better than cure” is still the primary call to action in the global strategy to address dementia until the healthcare system can universalize access to possible future treatments [3]. Besides aging, genetics, and family history, as estimated by the Lancet Commission, approximately 45% of dementia cases could be attributed to 14 modifiable risks [4]. Specific interventions can help prevent or delay cognitive decline and dementia [5, 6]. Metabolic disorders, such as obesity and hyperglycemia, are closely related to changes in brain structure, including cortical surface area, thickness, and subcortical volumes. These modifications not only accelerate the process of brain aging but also substantially increase the risk of developing neurodegenerative diseases [7]. From 2000 to 2021, the number of global all-age disability-adjusted life years (DALYs) attributable to metabolic risks increased from 319 million to 476 million, representing a rise of nearly 50%. High fasting plasma glucose (FPG) and high body mass index (BMI) ranked fifth and sixth among the 88 risk factors impacting the global disease burden, accounting for 5.4% and 4.5% of total DALYs, respectively [8]. Several studies have evidence that the disease burden of dementia is increased by elevated levels of exposure to various metabolic risk factors [9–11]. The 2024 report on dementia prevention, intervention, and care research further emphasizes that approximately 3% of dementia cases can be related to obesity and diabetes [4]. Additionally, the metabolic risk distribution differs significantly among populations of varying ages, genders, and regions due to physiological alterations, accumulated lifestyle influences, and disparities in healthcare accessibility. This variance has an indirect impact on the epidemiological trends in the burden of dementia. Currently, a subset of studies focuses on analyzing the worldwide and region-specific impact of AD and other dementias [12, 13], and another subgroup reports on the contribution of risks such as high FPG, high BMI, and others to the global burden of disease [14, 15]. Additionally, some studies combine specific risks with diseases, for instance, the burden of dementia attributed to smoking [16]. Metabolic risks are significant contributors to dementia, and early intervention targeting the metabolic risk factor and good metabolic health alleviates the burden of dementia and social costs [17]. However, detailed investigations into the burden of dementia related to metabolic risks and their classifications, including high FPG and high BMI, remain limited. Consequently, this study aims to fill the gap in this area by utilizing Global Burden of Disease Study (GBD) 2021 data to assess the global burden and trends of AD and other dementias attributed to metabolic risks, including high FPG and high BMI. Moreover, it intended to compare the differences in dementia burden among socioeconomic, geographical, gender, and age levels. This research is crucial in guiding the targeting of initiatives to implement prevention, intervention, and care to address the rising burden of dementia attributed to specific risk factors. Methods Data source Data on the burden of AD and other dementias caused by metabolic risks were extracted by applying the Global Health Data Exchange GBD Results Tool (http://ghdx.healthdata.org/GBD-results-tool). GBD 2021 provides comprehensive global health data for 371 diseases and injuries across 204 countries and territories, including 21 countries with subnational locations [8]. Data were obtained from verbal autopsies, household surveys, vital registration systems, disease-specific registries, health service contact records, and additional sources. Moreover, GBD 2021 is consistent with the recommendations of the Guidelines for Accurate and Transparent Health Estimates Reporting. Previous studies have extensively documented the comprehensive data sources and detailed analytical methodologies employed in GBD 2021 [18]. The leading pathological causes of dementia include AD, vascular dementia, Lewy body dementia, and frontotemporal dementia [19]. AD is the most common type of dementia. The ICD-10 assigned distinct illness codes to AD and other dementias in the GBD, including F00, F01, F02, F03, G30, and G31 [20]. The GBD comparative risk assessment framework identified two metabolic risks for AD and other dementias: high FPG and high BMI. High FPG was defined by the GBD 2021 as any level beyond the theoretical minimum-risk exposure level (TMREL) of 4.9–5.3 mmol/L, and high BMI as any BMI exceeding 20 to 23 kg/m2 [21, 22]. Estimation of disease burden Data covering AD and other dementias caused by metabolic risks from 1990 to 2021 included the number of deaths, DALYs, and corresponding age-standardized mortality rate (ASMR) and age-standardized DALY rate (ASDR), as well as the socio-demographic index (SDI), which covered 21 GBD regions and 204 countries and territories worldwide. GBD 2021 assessed associations between 88 risk factors and 155 health outcomes, resulting in a comprehensive analysis of 631 risk-outcome pairs. The study generated Summary Exposure Values, Relative Risks, Population Attributable Fractions, risk-attributable burdens measured in DALYs, and mortality counts. The introduction of the Burden of Proof Risk Function (BPRF) analyses addressed inter-study heterogeneity. Detailed methodologies and data about attributable risk burdens are thoroughly documented [8]. SDI and decomposition methodology Each nation’s SDI was computed by considering economic growth, educational attainment, and fertility rate [23]. The SDI classified 204 countries and territories into five quintiles (0 to 1: low, low-middle, middle, high-middle, and high). Furthermore, the countries and territories were grouped into 21 regions according to their geographical proximity and epidemiological similarities. Our study used decomposition analysis to determine the factors influencing changes in aging-related disease burdens [24]. Through this study, the differences in the overall disease burden between the populations in 1990 and 2021 may be determined, as well as the additive impact of each group’s changes in factors [25]. We employed decomposition methodology to analyze changes in the burden of dementias due to high FPG and high BMI, decomposing these by population age structure, population growth, and epidemiologic changes, thereby quantifying the impact of each component on the overall change in DALYs. Statistical analyses The metabolism-attributable burden of dementias was quantified utilizing absolute numbers and age-standardized rates for death and DALY. Each parameter was presented with a 95% uncertainty interval (UI), calculated as the 2.5th and 97.5th percentiles of 1,000 ordered estimates. To illustrate the trajectory of the disease burden from 1990 to 2021, the estimated average percentage change (EAPC) of age-standardized rates was adopted [26, 27]. The equation for the linear regression model is y = α + βX + ε. Here, X indicates the calendar year, Y denotes the natural logarithm of ASDR or ASMR, and ε for the error term. EAPC was computed as 100×(exp(β)-1), and a 95% confidence interval (CI) is provided by the linear regression model. Additionally, we examined the association between SDI and dementias related to high FPG and high BMI worldwide and in various locations between 1990 and 2021. All statistical analyses were conducted using R version 4.3.1, with a significance threshold set at P < 0.05. Results Metabolism-attributable global burden of AD and other dementias Between 1990 and 2021, the deaths related to metabolism-attributable AD and other dementias increased from 98,608 (95% UI: 2,768 − 335,849) to 399,824 (95% UI: 3,257-1,345,606) and DALYs rose from 1,995,430 (95% UI: 107,297-5,795,530) to 7,449,906 (95% UI: 71,764 − 21,026,713), with increases of 4.1 times and 3.7 times, respectively (Tables S1). In 2021, the ASMR and ASDR for AD and other dementias caused by high FPG globally were 3.73 (95% UI: 0.15–11.84) and 66.42 (95% UI: 3.83-178.85), respectively, and for high BMI, were 1.79 (95% UI: -0.27-7.44) and 32.86 (95% UI: -5.97-115.18). The Deaths and DALYs in 1990 and 2021 are shown in Supplementary Tables S2 and S3. From 1990 to 2021, the ASMR due to high FPG and high BMI showed an upward pattern, with the EAPC being 1.20 (95% CI: 1.11–1.29) and 1.17 (95% CI: 1.15–1.20), respectively. The EAPC for ASDR was 1.18 (95% CI: 1.09–1.26) and 1.32 (95% CI: 1.30–1.35), respectively (Tables 1 and 2). Table 1The global burden of Alzheimer’s disease and other dementias attributed to high fasting plasma glucose in 2021 and the temporal trends from 1990 to 2021LocationASMR in 2021(per 100,000)ASDR in 2021(per 100,000)EAPC ofASMR (%)EAPC ofASDR (%)Global3.73(0.15–11.84)66.42(3.83-178.85)1.2(1.11–1.29)1.18(1.09–1.26)SexMale3.26(0.13–10.51)57.71(3.29-155.61)1.25(1.16–1.33)1.21(1.13–1.28)Female4.03(0.17–12.61)72.55(4.21–193.7)1.21(1.12–1.3)1.2(1.11–1.29)Socio-Demographic IndexLow SDI2.83(0.10–9.31)49.47(2.52-139.57)1.34(1.28–1.39)1.20(1.16–1.23)Low-middle SDI3.19(0.12–10.43)57.36(3.09-158.52)1.72(1.68–1.76)1.55(1.52–1.58)Middle SDI3.42(0.13–10.92)63.35(3.6-172.97)0.87(0.8–0.94)0.88(0.81–0.95)High-middle SDI3.54(0.14–11.11)64.33(3.8-170.88)1.09(0.95–1.22)1.16(1.03–1.28)High SDI4.27(0.18–13.27)75.11(4.45-198.51)1.36(1.25–1.47)1.33(1.22–1.43)GBD regionAndean Latin America2.07(0.08–6.73)39.74(2.27-108.36)1.85(1.74–1.96)1.85(1.74–1.96)Australasia3(0.13–9.17)53.45(3.37-140.67)1(0.95–1.05)0.9(0.86–0.95)Caribbean2.77(0.11–9.07)54.44(3.15-143.84)0.52(0.5–0.54)0.5(0.47–0.52)Central Asia2.67(0.09–9.01)50.89(2.64-148.85)2.44(2.29–2.59)2.5(2.36–2.63)Central Europe3.52(0.14–11.21)65.91(3.96-171.31)1.29(1.24–1.34)1.29(1.23–1.34)Central Latin America2.91(0.11–9.44)59.09(3.48-158.37)0.47(0.43–0.5)0.44(0.41–0.47)Central Sub-Saharan Africa4.7(0.18–15.26)80.9(4.25-226.58)0.93(0.85–1.01)0.9(0.84–0.97)East Asia3.62(0.14–11.46)66.37(3.89-176.69)0.39(0.24–0.55)0.59(0.44–0.75)Eastern Europe2.27(0.08–7.25)42.84(2.44-117.18)1.62(1.55–1.7)1.64(1.57–1.71)Eastern Sub-Saharan Africa2.57(0.09–8.60)43.8(2.07-126.35)0.83(0.81–0.86)0.83(0.79–0.86)High-income Asia Pacific4(0.19–11.88)68.17(4.29-174.66)0.13(0.07–0.18)0.2(0.12–0.29)High-income North America5.66(0.23–18.07)99.65(5.91-264.59)2.23(2.03–2.43)2.03(1.84–2.22)North Africa and Middle East4.89(0.19–15.67)91.57(5.33-245.55)1.51(1.45–1.57)1.54(1.48–1.59)Oceania4.01(0.15–13.44)75.67(4.18–205.9)0.32(0.3–0.33)0.35(0.33–0.37)South Asia2.87(0.1–9.42)51.08(2.72-142.69)1.74(1.70–1.77)1.48(1.45–1.5)Southeast Asia3.58(0.13–11.99)64.21(3.31-182.73)1.30(1.19–1.41)1.21(1.12–1.3)Southern Latin America3.15(0.12–10.08)58.30(3.42-154.79)1.49(1.45–1.53)1.44(1.4–1.48)Southern Sub-Saharan Africa3.56(0.12–12.35)64.33(3.31-187.21)1.14(1.02–1.25)1.22(1.11–1.33)Tropical Latin America4.04(0.17–12.44)76.27(4.36-204.86)0.83(0.78–0.89)0.85(0.81–0.89)Western Europe3.71(0.15–11.65)63.81(3.60-173.67)1.06(1-1.13)1.04(0.98–1.11)Western Sub-Saharan Africa2.36(0.08–8.03)40.06(1.99-116.54)1.48(1.4–1.55)1.46(1.4–1.53)ASMR, age-standardized mortality rate; ASDR, age-standardized DALY rate; EAPC, estimated annual percentage change; GBD, Global Burden of Disease; SDI, Socio-Demographic Index Table 1The global burden of Alzheimer’s disease and other dementias attributed to high fasting plasma glucose in 2021 and the temporal trends from 1990 to 2021LocationASMR in 2021(per 100,000)ASDR in 2021(per 100,000)EAPC ofASMR (%)EAPC ofASDR (%)Global3.73(0.15–11.84)66.42(3.83-178.85)1.2(1.11–1.29)1.18(1.09–1.26)SexMale3.26(0.13–10.51)57.71(3.29-155.61)1.25(1.16–1.33)1.21(1.13–1.28)Female4.03(0.17–12.61)72.55(4.21–193.7)1.21(1.12–1.3)1.2(1.11–1.29)Socio-Demographic IndexLow SDI2.83(0.10–9.31)49.47(2.52-139.57)1.34(1.28–1.39)1.20(1.16–1.23)Low-middle SDI3.19(0.12–10.43)57.36(3.09-158.52)1.72(1.68–1.76)1.55(1.52–1.58)Middle SDI3.42(0.13–10.92)63.35(3.6-172.97)0.87(0.8–0.94)0.88(0.81–0.95)High-middle SDI3.54(0.14–11.11)64.33(3.8-170.88)1.09(0.95–1.22)1.16(1.03–1.28)High SDI4.27(0.18–13.27)75.11(4.45-198.51)1.36(1.25–1.47)1.33(1.22–1.43)GBD regionAndean Latin America2.07(0.08–6.73)39.74(2.27-108.36)1.85(1.74–1.96)1.85(1.74–1.96)Australasia3(0.13–9.17)53.45(3.37-140.67)1(0.95–1.05)0.9(0.86–0.95)Caribbean2.77(0.11–9.07)54.44(3.15-143.84)0.52(0.5–0.54)0.5(0.47–0.52)Central Asia2.67(0.09–9.01)50.89(2.64-148.85)2.44(2.29–2.59)2.5(2.36–2.63)Central Europe3.52(0.14–11.21)65.91(3.96-171.31)1.29(1.24–1.34)1.29(1.23–1.34)Central Latin America2.91(0.11–9.44)59.09(3.48-158.37)0.47(0.43–0.5)0.44(0.41–0.47)Central Sub-Saharan Africa4.7(0.18–15.26)80.9(4.25-226.58)0.93(0.85–1.01)0.9(0.84–0.97)East Asia3.62(0.14–11.46)66.37(3.89-176.69)0.39(0.24–0.55)0.59(0.44–0.75)Eastern Europe2.27(0.08–7.25)42.84(2.44-117.18)1.62(1.55–1.7)1.64(1.57–1.71)Eastern Sub-Saharan Africa2.57(0.09–8.60)43.8(2.07-126.35)0.83(0.81–0.86)0.83(0.79–0.86)High-income Asia Pacific4(0.19–11.88)68.17(4.29-174.66)0.13(0.07–0.18)0.2(0.12–0.29)High-income North America5.66(0.23–18.07)99.65(5.91-264.59)2.23(2.03–2.43)2.03(1.84–2.22)North Africa and Middle East4.89(0.19–15.67)91.57(5.33-245.55)1.51(1.45–1.57)1.54(1.48–1.59)Oceania4.01(0.15–13.44)75.67(4.18–205.9)0.32(0.3–0.33)0.35(0.33–0.37)South Asia2.87(0.1–9.42)51.08(2.72-142.69)1.74(1.70–1.77)1.48(1.45–1.5)Southeast Asia3.58(0.13–11.99)64.21(3.31-182.73)1.30(1.19–1.41)1.21(1.12–1.3)Southern Latin America3.15(0.12–10.08)58.30(3.42-154.79)1.49(1.45–1.53)1.44(1.4–1.48)Southern Sub-Saharan Africa3.56(0.12–12.35)64.33(3.31-187.21)1.14(1.02–1.25)1.22(1.11–1.33)Tropical Latin America4.04(0.17–12.44)76.27(4.36-204.86)0.83(0.78–0.89)0.85(0.81–0.89)Western Europe3.71(0.15–11.65)63.81(3.60-173.67)1.06(1-1.13)1.04(0.98–1.11)Western Sub-Saharan Africa2.36(0.08–8.03)40.06(1.99-116.54)1.48(1.4–1.55)1.46(1.4–1.53)ASMR, age-standardized mortality rate; ASDR, age-standardized DALY rate; EAPC, estimated annual percentage change; GBD, Global Burden of Disease; SDI, Socio-Demographic Index The global burden of Alzheimer’s disease and other dementias attributed to high fasting plasma glucose in 2021 and the temporal trends from 1990 to 2021 ASMR, age-standardized mortality rate; ASDR, age-standardized DALY rate; EAPC, estimated annual percentage change; GBD, Global Burden of Disease; SDI, Socio-Demographic Index Table 2The global burden of Alzheimer’s disease and other dementias attributed to high body mass index in 2021 and the temporal trends from 1990 to 2021LocationASMR in 2021(per 100,000)ASDR in 2021(per 100,000)EAPC ofASMR (%)EAPC ofASDR (%)Global1.79(-0.27-7.44)32.86(-5.97-115.18)1.17(1.15–1.2)1.32(1.3–1.35)SexMale1.29(-0.15-5.45)23.18(-3.28-82.98)2.09(2.06–2.12)2.12(2.09–2.14)Female2.12(-0.35-8.69)39.91(-8.02-138.91)1.01(0.97–1.05)1.18(1.14–1.21)Socio-Demographic IndexLow SDI0.51(0-2.78)9.71(-0.3-44.12)4.54(4.39–4.68)4.23(4.15–4.31)Low-middle SDI0.93(-0.09-4.12)17.45(-2.23-64.44)3.45(3.34–3.56)3.34(3.25–3.42)Middle SDI1.33(-0.15-5.77)25.94(-3.57-95)3.66(3.63–3.69)3.72(3.68–3.75)High-middle SDI2.16(-0.35-8.76)40.08(-8.05-138.02)1.31(1.29–1.32)1.38(1.36–1.4)High SDI2.28(-0.41-9.21)42.75(-9.34-145.86)0.71(0.67–0.76)0.83(0.79–0.86)GBD regionAndean Latin America1.2(-0.18-4.91)25.1(-5.08-86.6)3.01(2.88–3.13)2.66(2.55–2.76)Australasia2.78(-0.61-10.94)50.34(-12.82-172.03)1.55(1.44–1.66)1.38(1.29–1.47)Caribbean1.27(-0.21-5.36)26.73(-5.87-92.62)2.5(2.42–2.57)2.26(2.19–2.33)Central Asia2.12(-0.44-8.52)41.31(-10.15-139.18)0.76(0.69–0.83)0.76(0.69–0.82)Central Europe2.44(-0.55-9.59)47.07(-11.91-156.43)0.88(0.84–0.92)0.84(0.8–0.88)Central Latin America1.86(-0.36-7.44)38.61(-9.92-127.73)1.98(1.93–2.04)1.82(1.78–1.86)Central Sub-Saharan Africa1.44(-0.21-7.21)26.42(-4.86-114.24)5.82(5.78–5.86)5.39(5.35–5.43)East Asia1.26(-0.07-5.89)24.72(-1.79-98.13)9.11(8.67–9.55)9.18(8.74–9.63)Eastern Europe2.69(-0.66-10.34)52.26(-14.50-171.03)1.18(1.12–1.24)1.18(1.11–1.24)Eastern Sub-Saharan Africa0.58(-0.02-3.11)11.49(-0.17-52.07)5.75(5.56–5.94)5.42(5.25–5.59)High-income Asia Pacific0.69(-0.01-3.45)12.89(-0.11-55.94)3.27(3.25–3.29)3.37(3.35–3.39)High-income North America3.62(-0.89-14.13)66.93(-18.36-222.91)1.16(1.07–1.25)1.08(0.99–1.18)North Africa and Middle East3.2(-0.81-12.67)61.99(-18.35-207.22)1.78(1.72–1.84)1.8(1.76–1.84)Oceania0.99(-0.09-4.12)20.7(-2.54-72.73)1.06(0.97–1.16)1.19(1.14–1.24)South Asia0.37(-0.01-1.93)7.36(-0.19-32.12)9.62(9.05–10.20)8.92(8.36–9.49)Southeast Asia0.51(-0.01-2.42)10.93(-0.1-44.07)11.12(10-12.25)8.74(8.11–9.38)Southern Latin America2.39(-0.5-9.4)45.66(-12.31-153.61)1.43(1.38–1.48)1.35(1.3–1.4)Southern Sub-Saharan Africa2.8(-0.74-11.86)52.39(-14.92-192.78)2.11(1.99–2.23)1.93(1.84–2.02)Tropical Latin America2.76(-0.51-11.16)52.95(-12.32-184.34)2.61(2.45–2.78)2.31(2.17–2.45)Western Europe2.52(-0.41-9.96)44.13(-9.28-147.19)1.1(1.04–1.16)1.04(0.99–1.1)Western Sub-Saharan Africa1.19(-0.15-5.37)20.17(-3.04-80.38)3.42(3.39–3.45)3.14(3.12–3.16)ASMR, age-standardized mortality rate; ASDR, age-standardized DALY rate; EAPC, estimated annual percentage change; GBD, Global Burden of Disease; SDI, Socio-Demographic Index Table 2The global burden of Alzheimer’s disease and other dementias attributed to high body mass index in 2021 and the temporal trends from 1990 to 2021LocationASMR in 2021(per 100,000)ASDR in 2021(per 100,000)EAPC ofASMR (%)EAPC ofASDR (%)Global1.79(-0.27-7.44)32.86(-5.97-115.18)1.17(1.15–1.2)1.32(1.3–1.35)SexMale1.29(-0.15-5.45)23.18(-3.28-82.98)2.09(2.06–2.12)2.12(2.09–2.14)Female2.12(-0.35-8.69)39.91(-8.02-138.91)1.01(0.97–1.05)1.18(1.14–1.21)Socio-Demographic IndexLow SDI0.51(0-2.78)9.71(-0.3-44.12)4.54(4.39–4.68)4.23(4.15–4.31)Low-middle SDI0.93(-0.09-4.12)17.45(-2.23-64.44)3.45(3.34–3.56)3.34(3.25–3.42)Middle SDI1.33(-0.15-5.77)25.94(-3.57-95)3.66(3.63–3.69)3.72(3.68–3.75)High-middle SDI2.16(-0.35-8.76)40.08(-8.05-138.02)1.31(1.29–1.32)1.38(1.36–1.4)High SDI2.28(-0.41-9.21)42.75(-9.34-145.86)0.71(0.67–0.76)0.83(0.79–0.86)GBD regionAndean Latin America1.2(-0.18-4.91)25.1(-5.08-86.6)3.01(2.88–3.13)2.66(2.55–2.76)Australasia2.78(-0.61-10.94)50.34(-12.82-172.03)1.55(1.44–1.66)1.38(1.29–1.47)Caribbean1.27(-0.21-5.36)26.73(-5.87-92.62)2.5(2.42–2.57)2.26(2.19–2.33)Central Asia2.12(-0.44-8.52)41.31(-10.15-139.18)0.76(0.69–0.83)0.76(0.69–0.82)Central Europe2.44(-0.55-9.59)47.07(-11.91-156.43)0.88(0.84–0.92)0.84(0.8–0.88)Central Latin America1.86(-0.36-7.44)38.61(-9.92-127.73)1.98(1.93–2.04)1.82(1.78–1.86)Central Sub-Saharan Africa1.44(-0.21-7.21)26.42(-4.86-114.24)5.82(5.78–5.86)5.39(5.35–5.43)East Asia1.26(-0.07-5.89)24.72(-1.79-98.13)9.11(8.67–9.55)9.18(8.74–9.63)Eastern Europe2.69(-0.66-10.34)52.26(-14.50-171.03)1.18(1.12–1.24)1.18(1.11–1.24)Eastern Sub-Saharan Africa0.58(-0.02-3.11)11.49(-0.17-52.07)5.75(5.56–5.94)5.42(5.25–5.59)High-income Asia Pacific0.69(-0.01-3.45)12.89(-0.11-55.94)3.27(3.25–3.29)3.37(3.35–3.39)High-income North America3.62(-0.89-14.13)66.93(-18.36-222.91)1.16(1.07–1.25)1.08(0.99–1.18)North Africa and Middle East3.2(-0.81-12.67)61.99(-18.35-207.22)1.78(1.72–1.84)1.8(1.76–1.84)Oceania0.99(-0.09-4.12)20.7(-2.54-72.73)1.06(0.97–1.16)1.19(1.14–1.24)South Asia0.37(-0.01-1.93)7.36(-0.19-32.12)9.62(9.05–10.20)8.92(8.36–9.49)Southeast Asia0.51(-0.01-2.42)10.93(-0.1-44.07)11.12(10-12.25)8.74(8.11–9.38)Southern Latin America2.39(-0.5-9.4)45.66(-12.31-153.61)1.43(1.38–1.48)1.35(1.3–1.4)Southern Sub-Saharan Africa2.8(-0.74-11.86)52.39(-14.92-192.78)2.11(1.99–2.23)1.93(1.84–2.02)Tropical Latin America2.76(-0.51-11.16)52.95(-12.32-184.34)2.61(2.45–2.78)2.31(2.17–2.45)Western Europe2.52(-0.41-9.96)44.13(-9.28-147.19)1.1(1.04–1.16)1.04(0.99–1.1)Western Sub-Saharan Africa1.19(-0.15-5.37)20.17(-3.04-80.38)3.42(3.39–3.45)3.14(3.12–3.16)ASMR, age-standardized mortality rate; ASDR, age-standardized DALY rate; EAPC, estimated annual percentage change; GBD, Global Burden of Disease; SDI, Socio-Demographic Index The global burden of Alzheimer’s disease and other dementias attributed to high body mass index in 2021 and the temporal trends from 1990 to 2021 ASMR, age-standardized mortality rate; ASDR, age-standardized DALY rate; EAPC, estimated annual percentage change; GBD, Global Burden of Disease; SDI, Socio-Demographic Index In 2021, across most age groups globally, the deaths and the corresponding ASMR due to metabolic factors in dementias were higher in females than in males (Fig. 1). The deaths increased with age, peaking between 85 and 89 years old, after which it started to fall. Age-related increases in ASMR led to the highest levels in the age group over 95. Figure S1 illustrates the proportion of deaths and DALYs attributable to metabolism-related AD and other dementias relative to the total deaths and DALYs across different age categories. The ASMR and ASDR in men and women indicated a rising trend from 1990 to 2021 (Fig. 2). The EAPC for males (high FPG: 1.25; high BMI: 2.09) was higher than that for females (high FPG: 1.21; high BMI: 1.01). The EAPC for ASDR exhibited similar characteristics (Tables 1 and 2). Fig. 1The global burden of Alzheimer’s disease and other dementias due to (A) high fasting plasma glucose and (B) high body mass index among different sexes and age groups. SDI, Socio-Demographic Index The global burden of Alzheimer’s disease and other dementias due to (A) high fasting plasma glucose and (B) high body mass index among different sexes and age groups. SDI, Socio-Demographic Index Fig. 2The global trends in age-standardized rate for metabolism-related Alzheimer’s disease and other dementias from 1990 to 2021 The global trends in age-standardized rate for metabolism-related Alzheimer’s disease and other dementias from 1990 to 2021 Metabolism-attributable burden of AD and other dementias at the regional and national levels In 2021, The greatest ASMR for metabolism-related AD and other dementias was in High-income North America (Fig. S2). The ASMR of high FPG and high BMI were 5.66 (95% UI: 0.23–18.07) and 3.62 (95% UI: -0.0.89–14.13) in High-income North America, respectively; ASDR also showed the same result. The EAPCs of age-standardized rates for dementias caused by high FPG and high BMI were more significant than 0 in all 21 GBD regions, showing an increasing trend from 1990 to 2021. The region with the fastest increase in ASMR (EAPC: 2.44, 95% CI: 2.29–2.59) and ASDR (EAPC: 2.50, 95% CI: 2.36–2.63) caused by high FPG was Central Asia, followed by High-income North America and Andean Latin America. The three regions with the most significant upward trend in ASMR caused by high BMI were. Southeast Asia (EAPC: 11.12, 95% CI: 10.00-12.25), South Asia (EAPC: 9.62, 95% CI: 9.05–10.20), and East Asia (EAPC: 9.11, 95% CI: 8.67–9.55) were the three regions with the most significant upward trend in ASMR caused by high BMI, with the ASDR showing similar results (Tables 1 and 2). The changes in ASMR of AD and other dementias due to metabolic factors from 1990 to 2021 vary by country or region. For the burden of high FPG-related AD and other dementias, only four countries—Cyprus(EAPC,-0.48), Mexico(EAPC,-0.10), Cook Islands (EAPC, -0.07), and Norway(EAPC,-0.01)—showed a decrease in ASMR. Additionally, 200 countries or territories observed a rising trend in ASMR from 1990 to 2021. Georgia saw the fastest growth, with an EAPC of 3.50, followed by Greenland (EAPC, 3.46) and Luxembourg (EAPC, 3.13). Rwanda (EAPC, 12.31), Mozambique (EAPC, 11.51), and Angola (EAPC, 10.78) are the three countries with the most significant increase in ASMR attributed to high BMI (Fig. 3). Fig. 3The global spatial distribution of Alzheimer’s disease and other dementias due to metabolic risks across 204 countries and territories. The ASMR (A) and corresponding EAPC (B) of high fasting plasma glucose. The ASMR (C) and corresponding EAPC (D) of high body mass index. ASMR, age-standardized mortality rate; EAPC, estimated annual percentage change The global spatial distribution of Alzheimer’s disease and other dementias due to metabolic risks across 204 countries and territories. The ASMR (A) and corresponding EAPC (B) of high fasting plasma glucose. The ASMR (C) and corresponding EAPC (D) of high body mass index. ASMR, age-standardized mortality rate; EAPC, estimated annual percentage change Metabolism-attributable burden of AD and other dementias at different SDI levels Across 21 GBD regions, we investigated the association between SDI and the disease burden of AD and other dementias caused by high FPG and high BMI. The findings demonstrated that ASMR and ASDR rose when SDI increased (P<0.001) (Fig. 4 and S3). In 2021, the ASMR and ASDR were highest in the high SDI regions and lowest in the low SDI regions across all SDI regions. The ASMR and ASDR in the five SDI regions indicated an upward trend from 1990 to 2021. High FPG-related ASMR in the low-middle SDI region had the fastest rising rate (EAPC, 1.72), high BMI-related ASMR in the low SDI region had the fastest rising rate (EAPC, 4.54), and the situation was the same for ASDR (Tables 1 and 2). Fig. 4The association between Socio-Demographic Index and ASMR of metabolism-related Alzheimer’s disease and other dementias across 21 GBD regions. GBD, Global Burden of Disease; ASMR, age-standardized mortality rate The association between Socio-Demographic Index and ASMR of metabolism-related Alzheimer’s disease and other dementias across 21 GBD regions. GBD, Global Burden of Disease; ASMR, age-standardized mortality rate By decomposing the changes in DALYs for high FPG-attributable AD and other dementias from 1990 to 2021, it is shown that the epidemiological changes in all five SDI regions are on the rise. The contribution of population age structure was highest in the high SDI region (28.12%) and lowest in the low SDI region (2.45%). Conversely, population growth had the most significant influence in the low SDI region (66.82%) and the most negligible impact in the high SDI region (40.28%). Population growth was the primary driver of DALY changes in all SDI regions. Regarding changes in DALYs related to high BMI, epidemiological changes (56.63%) were the predominant factor driving the trend in the low SDI region, followed by population growth (44.15%). In comparison, the contribution of population age structure was negative (-0.78%). Differently, in the high SDI region, changes in DALYs were primarily propelled by population growth (44.45%), followed by population age structure (30.06%), and then epidemiological changes (25.49%) (Fig. 5). Fig. 5Decomposition analysis of changes in the DALYs of Alzheimer’s disease and other dementias attributed to (A) high fasting plasma glucose and (B) high body mass index between 1990 and 2021 globally and by SDI quintile. DALYs, disability-adjusted life-years; SDI, Socio-Demographic Index Decomposition analysis of changes in the DALYs of Alzheimer’s disease and other dementias attributed to (A) high fasting plasma glucose and (B) high body mass index between 1990 and 2021 globally and by SDI quintile. DALYs, disability-adjusted life-years; SDI, Socio-Demographic Index Discussion This study comprehensively estimates the burden of metabolism-related AD and other dementias from 1990 to 2021. Globally, the ASMR and ASDR for AD and other dementias caused by high FPG and high BMI are increasing, with considerable variations between age groups, genders, and regions. On the one hand, this trend is driven primarily by an aging population, improved healthcare coverage, and improved diagnostics [13, 28]; on the other hand, increased exposure to the risks associated with obesity and metabolic syndrome, exceptionally high FPG and high BMI, exacerbates the burden of non-communicable neurological diseases such as dementia. A global study on risk-attributable burden published in The Lancet discovered that exposure to high BMI and high FPG rose annually at rates of 1.8% (1.6–1.9) and 1.3% (1.1–1.5), respectively [8]. Policies aiming at reducing metabolic risk factors worldwide may be more helpful in lowering disease burdens than those focusing on concerns such as unclean water, sanitation, and personal hygiene [29]. When setting and planning public health goals, policymakers and healthcare stakeholders should prioritize risk factors with considerable increases in exposure levels over the last 30 years and control obesity and diabetes to lower the metabolism-attributable burden of dementias. Our study reports that the burden of AD and other dementias due to high FPG and high BMI increases with age in both sexes, with a higher burden in females than in males. Changes in hormones and genetic susceptibility may explain sex differences in the risk of dementia [30]. Evidence has suggested that women’s estrogen levels fall dramatically after menopause and that changes in brain regions’ structure and function affect cognitive performance [31, 32]. There is also evidence that the APOE4 genotype poses a greater risk for AD in women than in men. APOE4-positive women show faster cognitive decline and higher Aβ deposition between 65 and 75 years of age, especially during menopause [33, 34]. Additionally, gender-specific societal duties and opportunities, such as education, occupations, and physical activities, have differing effects on men’s and women’s cognitive reserve [35, 36]. Interestingly, the burden of dementia due to high FPG and high BMI increased more markedly in men, which may be related to the gender distribution of obesity and diabetes. Over the past few decades, obesity and diabetes rates have increased more rapidly among men [37, 38]. Men tend to acquire more visceral fat and more giant fat cells than women and visceral fat is metabolically active, raising the risk of insulin resistance and metabolic illness [39, 40]. Furthermore, research has indicated that men are less compliant with self-monitoring blood glucose levels [41]. As a result, gender specificity should be carefully considered when assessing dementia risk and developing prevention. Between 1990 and 2021, the burden of AD and other dementias due to high FPG and high BMI has generally increased across all regions. The distribution of this disease burden is strongly related to the level of social and economic development. In high SDI regions, the ASMR and ASDR for metabolism-related dementia are the highest. This trend is partly attributed to the more pronounced aging population in developed countries, as well as higher rates of early diagnosis and reporting of dementia [42]. Additionally, diabetes and obesity are more common in developed countries [43, 44]. For instance, in high-income North America, the burden of dementia due to high FPG and high BMI was the highest among the 21 GBD regions, consistent with the level of exposure to metabolic risk factors. In the United States, the prevalence of diabetes among adults is approximately 11.6%, and the obesity rate is as high as 40% [45, 46]. Fast food and sugary drinks, high in calories, sugar, and fat, are standard components of the American diet. This unhealthy eating habit is more common in low-income families, which often have insufficient access to medical resources and lack an early diagnosis and effective management of obesity and diabetes than in high-income [47, 48]. Developing an equity-oriented framework for obesity and diabetes prevention is crucial. A critical proposition for public health policy formulation and implementation is ensuring that prevention initiatives benefit the populations most vulnerable to risk factors. Although the current burden of metabolism-related dementia is more significant in regions with high levels of economic development, our study suggests that the increasing trend is more pronounced in low and low-middle SDI regions and that it is highly likely that the future burden of the disease will shift from developed to developing countries. For example, some rapid social transformations in population growth, urbanization, and changes in lifestyles are gradually putting pressure on the healthcare and social security systems in countries of Southeast Asia and South Asia. However, inadequate health infrastructure, poor provision, and poor management of medical services with low education levels all contribute to a rapidly rising disease burden in these areas [49]. Given that lower-SDI regions are unable to allocate the same level of care resources for AD and other dementias as higher-SDI regions, it is urgent for health policymakers to develop more universal lifestyle intervention strategies and primary prevention measures and to seek the most cost-effective dementia control programs in high-burden, resource-limited settings. Additionally, studies have found that the primary factor contributing to the rise in DALYs caused by metabolism-related AD and other dementias is global population growth, particularly in low-SDI regions where the impact of population growth is more significant. Population age structure contributes the most to the change in DALYs in high-SDI regions, while its impact is much smaller in low-SDI and low-middle-SDI regions. What is clear, however, is that the DALY rate for age-specific metabolism-related dementias over time drives the increase in DALYs in different areas, which is consistent with previous research [28]. These results indicate that the distribution of metabolic risks has a significant effect on the disease burden of dementia. Currently, guidelines for reducing dementia risk focus on interventions at the individual level [50]. Nevertheless, this approach appears insufficient if metabolic risk factors continue to rise, thus necessitating more comprehensive policy, societal, and public health interventions. The changes in ASMR and ASDR from 1990 to 2021 GBD differed between regions at different levels of SDI. Inequalities in structure are prevalent in the identification, treatment, and care of dementia patients. Reducing the gap in the availability of health resources for dementia management and meeting the healthcare needs of patients is a crucial part of formulating public health policies for dementia. The study provides significant trends and differences in age, gender, regional, and socio-demographic index groups. Some crucial points deserve to be highlighted. Firstly, obesity is recognized as an essential risk factor for type 2 diabetes, and thus, the two health problems are often interrelated within a similar setting. Given the earlier onset trend of obesity and diabetes, along with their associated severe health consequences and long-term impacts, the early implementation of dementia prevention and control strategies with a life-course perspective should be thoroughly studied. Moreover, the emphasis has to be shifted to contextual or social solutions. Compared to intervention recommendations focusing on individual behaviors, a substantial fraction of the population exposed to metabolic risk is not sufficiently protected against the macro-determinants of obesity and diabetes. Finally, it is necessary to develop equity-oriented obesity and diabetes prevention frameworks to address the structural inequalities underlying the distribution of the disease burden. The study has a few limitations. First, the accuracy of our estimates may be influenced by sparse or unreliable data from specific regions, periods, or age groups, particularly in low-income areas with lower data quality and coverage. Second, in recent years, GBD has increasingly employed modeling processes to estimate regions with reduced data completeness and address reporting lags [18]. Third, exposure to high BMI is calculated using the distribution of BMI in the population at specific time points; however, midlife BMI is shown in studies to be the most significant risk factor. As a result, Future research should consider lagged BMI exposure to capture risk-outcome relationships better in prediction. Furthermore, our study focused on changes in metabolism-related dementia mortality and DALY rates, which are directly relevant to the development of dementia prevention strategies and the allocation of healthcare resources. However, predicting the future burden of metabolism-related dementia is also necessary and should be a theme for future research. Conclusion The global burden of AD and other dementias due to metabolic risk has continued to rise during the last three decades. While population growth and aging contribute to the disease burden, higher levels of metabolic risk exposure are also important factors to consider. These findings are helpful for countries or regions lacking studies on dementia burden and risk factor exposure to identify key risk factors for early intervention. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5 Supplementary Material 6 Supplementary Material 6